MVA-BN Vaccine: Durable Immunity & Booster Response at 5 Years

The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine, used to protect against mpox (formerly known as monkeypox) and smallpox, appears to offer sustained immune protection for at least five years after vaccination, according to a recent prospective study. Importantly, a single booster dose administered after five years significantly elevates antibody levels, suggesting a robust immune memory response. This finding offers encouraging news regarding the durability of protection from this third-generation smallpox vaccine.

Understanding the MVA-BN Vaccine and its Advantages

Mpox, a viral disease related to smallpox, gained global attention in 2022 with outbreaks reported in multiple countries. The MVA-BN vaccine, marketed under brand names like Jynneos in the US, Imvamune in Canada, and Imvanex in the EU, has become a crucial tool in controlling the spread of the virus. Unlike earlier smallpox vaccines, which used live vaccinia virus capable of replicating in humans and sometimes causing significant side effects, MVA-BN utilizes an attenuated (weakened) strain. This means the virus in the vaccine cannot fully reproduce within the body, leading to a much-improved safety profile. The World Health Organization (WHO) recommends MVA-BN vaccination for individuals at high risk of mpox exposure, including contacts of cases, and for laboratory personnel working with orthopoxviruses.

Study Details and Findings: Durable Immune Memory

The recent study, published in Medscape Medical News, investigated the longevity of the immune response generated by the MVA-BN vaccine. Researchers followed vaccinated individuals for five years, monitoring their B-cell memory responses – a key indicator of long-term immunity. The results demonstrated that the vaccine induced durable B-cell memory for up to five years. Administering a booster dose at the five-year mark resulted in a substantial increase in antibody levels, indicating a “boost” to the immune system’s ability to fight off the virus. While the full details of the study, including sample size and specific methodologies, are not yet widely available in public databases, the initial findings are promising.

What Does This Mean for Public Health?

The finding of sustained immunity is significant for several reasons. It suggests that the initial two-dose vaccination series may provide long-lasting protection against mpox, potentially reducing the need for frequent booster shots for the general population. However, it’s important to note that this study focused on immune memory and antibody levels, not necessarily on real-world protection against infection. Further research is needed to determine how well the vaccine protects against mpox over the long term, particularly as the virus evolves.

Mpox Risk and Vaccination Context

The 2022 mpox outbreak primarily affected men who have sex with men, but the virus can infect anyone through close contact with an infected person or contaminated materials. Modified vaccinia Ankara (MVA) is being used as a vaccine against both smallpox and mpox, offering a broader protective scope than previous generations of smallpox vaccines. The MVA-BN vaccine’s non-replicating nature makes it a safer option for individuals with certain health conditions or compromised immune systems for whom traditional vaccines might be contraindicated. It’s crucial to remember that vaccination is not 100% effective, and practicing safe behaviors, such as avoiding close contact with infected individuals and practicing good hygiene, remains important.

How the MVA-BN Vaccine Works: A Closer Glance

The MVA-BN vaccine is a third-generation smallpox vaccine. Traditional smallpox vaccines used a live virus that could replicate, sometimes causing adverse reactions. The MVA-BN vaccine, developed through over 500 passages of the vaccinia virus in chicken embryo fibroblasts, is highly attenuated. This attenuation process resulted in a virus that can stimulate an immune response but cannot complete its replication cycle in human cells. As explained by Wikipedia, this block in the viral life cycle prevents the release of fully formed virus particles, contributing to its improved safety profile. The MVA-BN virus can be genetically engineered to deliver antigens from other viruses, making it a versatile platform for developing vaccines against a range of diseases.

Vaccination Recommendations and WHO Guidance

The WHO Strategic Advisory Group of Experts (SAGE) currently recommends MVA-BN vaccination for individuals at high risk of mpox exposure during outbreaks and for laboratory personnel working with orthopoxviruses. The WHO notes that broader preventive use in non-outbreak settings will require further epidemiological and vaccination-related evidence. The vaccine is manufactured by Bavarian Nordic A/S under the brands Jynneos®, Imvamune®, and Imvanex®, and the WHO’s recommendations apply to all three brands.

What Comes Next: Ongoing Surveillance and Research

Public health officials continue to monitor mpox cases globally and track the effectiveness of the MVA-BN vaccine. Ongoing surveillance efforts are crucial for identifying any potential changes in the virus and assessing the need for updated vaccine formulations or booster strategies. Further research is also needed to determine the optimal timing and frequency of booster doses, as well as the vaccine’s effectiveness in different populations. The WHO and national health authorities will continue to review emerging data and update vaccination recommendations as needed. Individuals should stay informed about the latest public health guidance and consult with a qualified healthcare professional for personalized advice.